Search results
Results From The WOW.Com Content Network
The disease was first reported in 1961 by T.A. Waldmann. He described 18 cases of patients having a low level 131 I-albumin. [ 9 ] [ 10 ] Biopsies of the small intestine were examined under the microscope and found various levels of dilatation of the lymph vessels.
When it occurs in the intestines it is known as intestinal lymphangiectasia, colloquially recognized as Waldmann's disease in cases where there is no secondary cause. [3] The primary defect lies in the inability of the lymphatic system to adequately drain lymph, resulting in its subsequent accumulation and leakage into the intestinal lumen. [ 3 ]
Prognosis improved by early supportive treatments as seen in the West African epidemic and the Kivu outbreak. [23] [24] Marburg virus disease – all outbreaks combined Viral Untreated [23–90]% 23% in 1967 when it was first identified and 90% in 2004-2005 when the worst outbreak of the disease occurred.
Survival rate is a part of survival analysis.It is the proportion of people in a study or treatment group still alive at a given period of time after diagnosis. It is a method of describing prognosis in certain disease conditions, and can be used for the assessment of standards of therapy.
The five-year survival rate is a type of survival rate for estimating the prognosis of a particular disease, normally calculated from the point of diagnosis. [1] Lead time bias from earlier diagnosis can affect interpretation of the five-year survival rate.
The prognosis of Waterhouse–Friderichsen syndrome varies by severity of the illness. Around 15% of patients with significant acute bilateral adrenal bleeding experience a fatal outcome. In cases where diagnosis and appropriate treatment are delayed, the case fatality rate approaches 50%.
As reported by Dispenzieri et al. [4] Mayo Clinic treatment regimens are tailored to treat the clinical manifestations and prognosis for the rate of progression of the POEMS syndrome in each patient. In rare cases, patients may have minimal or no symptoms at presentation or after successful treatment of their disorder.
In other series from Europe, the rate of decline in FEV1 was considerably higher, estimated at approximately 100 to 120 mL/yr. [6] [129] [130] In the MILES trial, patients in the placebo group lost 134 cc/yr. [35] There was some evidence in these studies that rate of decline in lung function correlates with initial DLCO, with menopausal status ...